Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil, Susan O’Brien, M.D., Verena Karsten, PhD, Alan K. Burnett, MD, FRCP, Francis Giles, MD

Blood (2008) 112 (11): 2960.

https://doi.org/10.1182/blood.V112.11.2960.2960

Published: 2008

Journal Articles

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies.

David A. Rizzieri, William Tse, Khuda D. Khan, Anjali Advani, Jon Donze, Verena Karsten, Robert B. Geller, Stanton L. Gerson

Blood (2006) 108 (11): 1971.

https://doi.org/10.1182/blood.V108.11.1971.1971

Published: 2006

Journal Articles

Effects of Initial Treatment on Survival among Elderly AML Patients: Findings from the SEER-Medicare Database.

Joseph Menzin, PhD, Luke Boulanger, M.A., Verena Karsten, Ph.D., Ann L. Cahill, PA-C, Craig E. Earle, M.D. MSc FRCP(C)

Blood (2006) 108 (11): 1973.

https://doi.org/10.1182/blood.V108.11.1973.1973

Published: 2006

Journal Articles

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Francis Giles, MD, Susan O’Brien, MD, David Rizzieri, MD, Judith Karp, MD, Maureen Cooper, MD, Ghulam Mufti, MD, Bonny Johnson, MSN, Verena Karsten, PhD, Norbert Vey, MD

Blood (2005) 106 (11): 2786.

https://doi.org/10.1182/blood.V106.11.2786.2786

Published: 2005

Journal Articles

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Francis Giles, MD, David Rizzieri, MD, Judith Karp, MD, Norbert Vey, MD, Khuda Khan, MD, Ghulam Mufti, MD, Diana Hudak, Verena Karsten, PhD, Susan O’Brien, MD

Blood (2005) 106 (11): 2787.

https://doi.org/10.1182/blood.V106.11.2787.2787

Published: 2005

NARROW

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies.

Effects of Initial Treatment on Survival among Elderly AML Patients: Findings from the SEER-Medicare Database.

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Email alerts

ASH Publications

American Society of Hematology

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies.

Effects of Initial Treatment on Survival among Elderly AML Patients: Findings from the SEER-Medicare Database.

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only